Setidegrasib is the first drug in the class of KRAS degraders that targets the KRAS G12D mutation in advanced tumors[1]. Instead of blocking the signal, this drug removes the protein itself caused by the KRAS mutation[1]. In a clinical study, the drug was administered intravenously once a week at the recommended dose of 600 milligrams[1]. In non-small cell lung cancer patients unresponsive to previous treatments, approximately one-third of patients responded to setidegrasib with an encouraging durability of effect, and approximately 60% of patients were alive at one year[1]. In patients with pancreatic cancer, approximately 25% responded to the drug and the median overall survival was 10 months[1]. The study demonstrated the safety and benefit of the drug in both types of cancer[1]. Based on the success of this initial trial, a global phase 3 randomized trial was initiated[1].